Clenz-Lyte

Generic name:polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride and potassium chloride
Dosage form: powder, for solution
Drug class:Laxatives

Medically reviewed by Drugs.com. Last updated on May 23, 2022.

DESCRIPTION:

Clenz-Lyte™ (Polyethylene Glycol 3350 and Electrolytes for Oral Solution) is a white powder in a 4 liter jug for reconstitution, containing 236 g polyethylene glycol 3350, 22.74 g sodium sulfate (anhydrous), 6.74 g sodium bicarbonate, 5.86 g sodium chloride and 2.97 g potassium chloride. When dissolved in water to a volume of 4 liters, Clenz-Lyte™ is an isosmotic solution, for oral administration, having a mildly salty taste. Clenz-Lyte™ is administered orally or via nasogastric tube as a gastrointestinal lavage.

CLINICAL PHARMACOLOGY:

Clenz-Lyte™ induces a diarrhea which rapidly cleanses the bowel, usually within four hours. The osmotic activity of polyethylene glycol 3350 and the electrolyte concentration result in virtually no net absorption or excretion of ions or water. Accordingly, large volumes may be administered without significant changes in fluid or electrolyte balance.

INDICATIONS AND USAGE:

Clenz-Lyte™ is indicated for bowel cleansing prior to colonoscopy and barium enema X-ray examination.

CONTRAINDICATIONS:

Clenz-Lyte™ is contraindicated in patients known to be hypersensitive to any of the components. Clenz-Lyte™ is contraindicated in patients with gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon or ileus.

WARNINGS:

No additional ingredients, e.g. flavorings, should be added to the solution. Clenz-Lyte™ should be used with caution in patients with severe ulcerative colitis.

PRECAUTIONS:

General:

Patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration should be observed during the administration of Clenz-Lyte™, especially if it is administered via nasogastric tube. If a patient experiences severe bloating, distention or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed to rule out these conditions before administration of...